Endpoints for clinical trials in type 1 diabetes drug development

Simple item page
dc.contributor.authorGalderisi, Alfonso
dc.contributor.authorMarks, Brynn E.
dc.contributor.authorDiMeglio, Linda A.
dc.contributor.authorde Beaufort, Carine
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2024-12-13T12:57:17Z
dc.date.available2024-12-13T12:57:17Z
dc.date.issued2024
dc.eprint.versionAuthor's manuscript
dc.identifier.citationGalderisi A, Marks BE, DiMeglio LA, de Beaufort C. Endpoints for clinical trials in type 1 diabetes drug development. Lancet Diabetes Endocrinol. 2024;12(5):297-299. doi:10.1016/S2213-8587(24)00097-4
dc.identifier.urihttps://hdl.handle.net/1805/45017
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/S2213-8587(24)00097-4
dc.relation.journalThe Lancet: Diabetes & Endocrinology
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectType 1 diabetes mellitus
dc.subjectDrug development
dc.subjectHypoglycemic agents
dc.subjectEndpoint determination
dc.titleEndpoints for clinical trials in type 1 diabetes drug development
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Galderisi2024Endpoints-AAM.pdf
Size:
454.37 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles